Skip to main content
BRTX
NASDAQ Industrial Applications And Services

VP of R&D secures 3-year employment agreement with $1.3M change-in-control severance

Arie Shkolnikov · Analysis by Wiseek AI
More coverage: Biotech Stocks · Healthcare
Sentiment info
Negative
Importance info
9
Price
$0.371
Mkt Cap
$8.981M
52W Low
$0.159
52W High
$2.045
52W Position info
133% above low
Off High info
82% below high
Rel. Volume info
0.1× avg
Market data snapshot near publication time

BRTX has more than doubled off its 52-week low of $0.159 on light trading volume (0.1× avg).

Summary

BioRestorative Therapies signed a new 3-year employment agreement for its VP of R&D, including a $575,000 salary and a potential $1.3 million severance package that triggers on a change in control, despite the company's severe financial challenges.


Key Events · Executive and Board Changes · BRTX

  • New Employment Agreement for VP R&D

    Francisco Silva, Vice President of Research and Development, entered into a new three-year employment agreement effective June 10, 2026.

  • Executive Compensation Details

    The agreement maintains an annual salary of $575,000 and includes eligibility for an annual cash bonus of up to 50% of salary.

  • Substantial Severance Package

    The agreement provides for a severance payment of 1.5 times the sum of salary and maximum bonus, totaling approximately $1.3 million, upon termination without cause or resignation for good reason.

  • Change-in-Control Trigger

    The severance package and full vesting of equity awards are triggered upon a change in control, regardless of whether employment terminates.


Analysis · BRTX · Industrial Applications And Services

BioRestorative Therapies, a company facing a 'going concern' warning, Nasdaq delisting risk, and recent dilutive actions, has entered into a new three-year employment agreement with its Vice President of Research and Development, Francisco Silva. The agreement maintains his $575,000 annual salary and includes a substantial severance package of approximately $1.3 million (1.5 times salary plus maximum bonus) that triggers upon termination without cause or a change in control, even if employment does not cease. This commitment represents a significant potential liability for a company with an $8.98 million market capitalization, raising concerns about executive compensation and corporate governance amidst ongoing financial distress and a pattern of generous executive bonuses.

At the time of this filing, BRTX was trading at $0.37 on NASDAQ in the Industrial Applications And Services sector, with a market capitalization of approximately $9M. The 52-week trading range was $0.16 to $2.05. This filing was assessed with negative market sentiment and an importance score of 9 out of 10.

View Main SEC Filing

Price Chart

Share this article

Copied!

BRTX - Latest Insights

BRTX
Jul 16, 2026, 5:33 PM EDT
Source: Wiseek News
Importance Score:
9
Price at Filing: $0.353
Real-time Price: $0.293 info
Change: -$0.060 (-17%) info
Market Cap: $7.057M info
BRTX
Jul 16, 2026, 5:30 PM EDT
Filing Type: 8-K
Importance Score:
9
Price at Filing: $0.353
Real-time Price: $0.293 info
Change: -$0.060 (-17%) info
Market Cap: $7.057M info
BRTX
Jun 12, 2026, 4:56 PM EDT
Filing Type: 8-K
Importance Score:
9
Price at Filing: $0.3706
Real-time Price: $0.293 info
Change: -$0.0776 (-21%) info
Market Cap: $7.057M info
BRTX
May 29, 2026, 5:13 PM EDT
Source: Wiseek News
Importance Score:
7
Price at Filing: $0.4598
Real-time Price: $0.293 info
Change: -$0.1668 (-36%) info
Market Cap: $7.057M info
BRTX
May 29, 2026, 5:07 PM EDT
Filing Type: 8-K
Importance Score:
9
Price at Filing: $0.4509
Real-time Price: $0.293 info
Change: -$0.1579 (-35%) info
Market Cap: $7.057M info